Search

Search Constraints

You searched for: Author/Creator van Rhee, Frits

Search Results

21. Monitoring treatment response and disease progression in myeloma with circulating cell‐free DNA. (10th November 2020)

22. Monitoring treatment response and disease progression in myeloma with circulating cell‐free DNA. (10th November 2020)

23. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?. (March 2016)

24. Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab. (31st October 2020)

26. Persistent bone marrow minimal residual disease as a "high‐risk" disease feature in multiple myeloma. Issue 9 (29th June 2021)

27. Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease. Issue 7 (16th May 2018)

28. Predictors of response to anti‐IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. (11th September 2018)

30. Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. Issue 6 (21st March 2022)